VIDEO: Vadadustat effective for CKD-related anemia in patients receiving dialysis

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

In the dialysis area, anemia is extremely common. At any given time, 80 to 90% of patients are getting ESA therapy and overwhelmingly they get IV iron on a regular basis. In this area, vadadustat (Vafseo, Akebia Therapeutics), another HIF-PHI or prolyl hydroxylase inhibitor that stabilizes HIF, does treat the anemia in place of using an ESA. This was approved in 2024 and should be available fairly soon here in 2025. That's not approved for the non-dialysis population. Although studies have used it in those populations and it can be effective, it's not approved in the United States. In other countries, HIF-PHIs are approved for non-dialysis CKD-related anemia.